A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study

A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study

BackgroundIAH0968 is an afucosylated anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody which improved the activity of antibody-dependent cellular cytotoxicity (ADCC) and superior anti-tumor efficacy.MethodsTo determine the maximum tolerated dose (MTD) with dose-limiting toxicity (DL...

Full description

Saved in:
Bibliographic Details
Main Authors: Na Song, Yuee Teng, Jing Shi, Zan Teng, Bo Jin, Jinglei Qu, Lingyun Zhang, Ping Yu, Lei Zhao, Jin Wang, Aodi Li, Linlin Tong, Shujie Jiang, Yang Liu, Liusong Yin, Xiaoling Jiang, Tie Xu, Jian Cui, Xiujuan Qu, Yunpeng Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Immunology
Subjects:
HER2
IAH0968
clinical study
safety
first-in-human
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1481326/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1481326/full

Similar Items